Back to top
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Bristol Myers Squibb Company (BMY) - free report >>
Johnson & Johnson (JNJ) - free report >>
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bristol Myers Squibb Company (BMY) - free report >>
Johnson & Johnson (JNJ) - free report >>
Image: Bigstock
Minerva Surges on Positive Results on Depression Candidate
Shares of Minerva Neurosciences, Inc. (NERV - Free Report) soared 233.3% after the company announced positive top-line results from a phase IIa trial on antidepressant drug candidate, MIN-117.
The candidate is being evaluated for major depressive disorder (MDD). The objective of the trial is to test efficacy, safety and tolerability of MIN-117 over six weeks of treatment. The randomized double-blind trial (n=84) tested two daily administered doses of MIN-117: 0.5 mg and 2.5 mg, in moderate to severe MDD patients in four European countries.
The results of the trial showed dose-dependent superiority of MIN-117 over placebo as measured by a change in the Montgomery-Asberg Depression Rating Scale (MADRS). The results of the trial also demonstrated that MIN-117 at the 0.5 milligrams (mg) daily dose had an effect size (magnitude of difference) as compared to the placebo group of 0.23, while the 2.5 mg daily dose had an effect size of 0.33. Consequently, MIN-117 met both the primary and secondary endpoints.
The candidate showed a favourable safety and tolerability profile.
Per the World Health Organization, MDD is the leading cause of disability worldwide and a significant contributor to the overall global disease burden, thereby emphasizing the need for therapies to treat it.
The successful results of the trial bode well for Minerva Neurosciences which does not have any approved products in its portfolio. Other candidates in the company’s pipeline include MIN-101, (currently in phase IIb for schizophrenia); MIN-202 (insomnia and the adjunctive MDD) among others.
We note that MIN-202 is being developed by Minerva in collaboration with Janssen Pharmaceutical NV, a Johnson & Johnson (JNJ - Free Report) undertaking.
Minerva Neurosciences presently carries a Zacks Rank #2 (Buy). A couple of other well-placed stocks in the health care sector are Pfizer Inc. (PFE - Free Report) and Bristol-Myers Squibb Company (BMY - Free Report) . Both companies sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>